FDA Scale-Up and Postapproval Changes (SUPAC) Guidelines Study Guide

FDA Scale-Up and Postapproval Changes (SUPAC) Guidelines Overview

Definition and Regulatory Scope:
- SUPAC represents the changes recommended by the United States Food and Drug Administration (US FDA) at the time of scale-up or post-approval of a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).
- During drug product development, batch sizes used in initial human studies are small and are gradually expanded through a scale-up process.
- Modifications made following approval in product composition, manufacturing process, manufacturing equipment, and site of manufacture are collectively classified under Scale-Up and Postapproval Changes (SUPAC).
Specific SUPAC Guideline Documents:
- SUPAC-IR: Guidance covering Immediate Release solid oral dosage forms.
- SUPAC-MR: Guidance covering Modified Release solid oral dosage forms.
- SUPAC-SS: Guidance covering Nonsterile Semisolid dosage forms.
Levels of Regulatory Changes:
- Level 1 (Minor Changes): Modifications unlikely to have a detectable impact or effect on drug product quality or performance.
- Level 2 (Moderate Changes): Modifications that could have a significant impact on drug product quality, safety, or efficacy.
- Level 3 (Major Changes): Modifications likely to have a significant impact on drug product identification, quality, purity, potency, safety, or efficacy.
Evaluation Tests for Changes:
- Application Test: Testing compendial and application release criteria.
- In Vitro Dissolution: Dissolution profile comparisons across specified media and time points.
- In Vivo Bioequivalence: In vivo bioequivalence studies required when in vitro profiles or testing are insufficient.
Types of Regulatory Filings:
- Annual Report (AR): Regulatory reporting mechanism for minor changes.
- Changes Being Effected Supplement (CBE / CBE-0 and CBE-30): Regulatory reporting mechanism for moderate changes.
- Prior Approval Supplement (PAS): Regulatory submission for major changes requiring agency approval prior to distribution.

Post-Approval Changes Framework Under USFDA Regulations (21 CFR 314.70 & Section 506A)

Regulatory Statutory Basis:
- Post-approval manufacturing, quality control, equipment, facility, product, and labeling changes are governed under Section 506A of the Federal Food, Drug, and Cosmetic Act and Title 21 of the Code of Federal Regulations (21 CFR 314.70).
- Post-approval changes established in approved NDAs or ANDAs are categorized into tier-based reporting frameworks depending on the potential risk to adversely affect product performance, strength, identification, potency, or purity as related to safety or efficacy.
Major Changes (Level 3 - Substantial Potential Risk):
- Definition: Modifications that have significant potential to adversely affect product identification, intensity, quality, excellence, purity, or potency.
- Filing Requirement: Requires a Prior Approval Supplement (PAS) submitted under 21 CFR 314.70(b).
- Distribution Condition: Formal FDA approval must be received prior to distributing or selling the drug product manufactured using the modification ("Tell, wait, and do after getting approval procedure").
- Expedited Review Provision: Applicants may request accelerated review for public health reasons or if delays cause extraordinary hardship. Accelerated approval is typically granted on the basis of exceptional difficulty caused by unforeseen, unavoidable events.
- Estimated Timeline for Approval:
- Without pre-approval inspection: $6\,months$ .
- With pre-approval inspection: $10\,months$ .
Moderate Changes (Level 2 - Moderate Potential Risk):
- Definition: Modifications encompassing a modest potential to adversely affect drug product safety, performance, strength, purity, or efficacy.
- Subcategories and Filing Requirements:
- CBE-30 (Changes Being Effected in 30 Days) submitted under 21 CFR 314.70(c)(5):
  - Requires supplement submission $30\,days$ prior to commercial distribution ("Tell, wait, and do procedure").
  - Distribution must be postponed if FDA notifies the applicant within $30\,days$ that a PAS is required or that information is missing, until required data is provided.
  - Estimated approval timeline: $30\,days$ (varies based on agency queries).
- CBE-0 (Changes Being Effected Immediately) submitted under 21 CFR 314.70(c)(6):
  - Allows product distribution immediately upon FDA receipt of the supplement ("Tell and do procedure").
  - Change can technically be implemented the next day after filing, but recommended best practice is to wait $15\,days$
- FDA Inspection Action: If FDA disapproves a CBE-30 or CBE-0 modification upon review or inspection, the agency may order the manufacturer to immediately cease distribution of products made with those disapproved changes.
Minor Changes (Level 1 - Minimal / Negligible Potential Risk):
- Definition: Modifications with limited or negligible ability to adversely affect quality, identification, purity, potency, or strength.
- Filing Requirement: Reported in the applicant's Annual Report under 21 CFR 314.70(d) ("Do and tell procedure").
- Distribution Condition: No FDA approval is required prior to distribution.
- Reporting Scope: A comprehensive list of minor changes must be reported annually starting from the drug approval date until the product is withdrawn from the market.
- Estimated Timeline for Approval: Not Applicable ( $\text{NA}$ ).

Summary Matrix of Post-Approval Reporting Categories

Major Change (Level 3):
- Supplement Type: Prior Approval Supplement (PAS).
- Regulatory Protocol: Tell, wait, and do after approval.
- Agency Notification: Before implementing change.
- Estimated Approval Timeline: $6\,months$ (no pre-approval inspection) or $10\,months$ (with pre-approval inspection).
Moderate Change - CBE-30 (Level 2):
- Supplement Type: Changes Being Effected in 30 Days Supplement.
- Regulatory Protocol: Tell, wait, and do.
- Agency Notification: Before implementing change ( $30\,days$ prior).
- Estimated Approval Timeline: $30\,days$ (timeline varies based on agency queries).
Moderate Change - CBE-0 (Level 2):
- Supplement Type: Changes Being Effected Supplement.
- Regulatory Protocol: Tell and do.
- Agency Notification: Implemented simultaneously with filing (best practice: wait $15\,days$ ).
- Estimated Approval Timeline: Immediate upon agency receipt.
Minor Change (Level 1):
- Supplement Type: Annual Report (AR).
- Regulatory Protocol: Do and tell.
- Agency Notification: Annually from approval date until product withdrawal.
- Estimated Approval Timeline: Not Applicable ( $\text{NA}$ ).

Workflow Flowchart of FDA Change Approval Process

Process Flow Step-by-Step:
- Initial Application Approval achieved as per 314.105.
- Post-approval changes proposed under 314.70.
- Identify Type of Chemistry, Manufacturing, and Controls (CMC) Change:
- Components and Composition
- Manufacturing site
- Manufacturing process
- Specifications
- Container and closure system
- Labeling
- Miscellaneous
- Categorize Risk Level of CMC Change:
- Minor Change
- Moderate Change
- Major Change
- Select Supplement Application Type:
- Major Change $\rightarrow$ Prior Approval Supplement (21 CFR 314.70(b))
- Moderate Change $\rightarrow$ Changes Being Effected (21 CFR 314.70(c)(5) for CBE-30 / 21 CFR 314.70(c)(6) for CBE-0)
- Minor Change $\rightarrow$ Annual Report (21 CFR 314.70(d))
- Submission and Review:
- Submission of Supplement Application as per 314.71.
- Official review executed by US FDA.
- Final Regulatory Decision:
- Approval: Distribution allowed.
- Rejection: Applicant must cease distribution of affected drug products immediately.

Level-Specific Guidelines by CMC Category

1. Components and Composition (Excipients Guidance)

Regulatory Note: Applies strictly to changes in excipients, not changes in active drug substance amount.
Level 1 Changes:
- Definition: Minor excipient changes unlikely to impact formulation quality or performance.
- Examples: Deletion or partial deletion of color or flavor ingredients; changes in printing ink.
- Chemistry Documentation: Application or compendial release testing; stability testing ( $1\,batch$ on long-term stability).
- Dissolution Testing: None beyond compendial/application requirements.
- Bioequivalence Testing: None.
- Filing: Annual Report.
Level 2 Changes:
- Definition: Excipient changes that could significantly impact formulation quality or performance.
- Chemistry Documentation: Application/compendial release, batch records, $3\,months$ accelerated stability data, and long-term stability for $1\,batch$
- Dissolution Testing:
- Case A (High Permeability / High Solubility): $\ge 85\%$ dissolution within $15\,min$
- Case B (Low Permeability / High Solubility): Multi-point dissolution profile at $15, 30, 45, 60, \text{ and } 120\,min$ (or until asymptote is reached).
- Case C (High Permeability / Low Solubility): Multi-point dissolution profiles across 5 separate media conditions: $0.1\,N\,HCl$ , USP buffer media at $pH\,4.5$ , $pH\,6.5$ , and $pH\,7.5$ , with justified surfactant if necessary.
- Bioequivalence Testing: None required if satisfied by Case A, Case B, or Case C dissolution.
- Filing: CBE supplement with accelerated stability data; Annual Report with long-term stability data.
Level 3 Changes:
- Definition: Excipient changes likely to significantly impact formulation quality or performance.
- Examples: Qualitative or quantitative excipient alterations in a narrow therapeutic index drug beyond specified ranges.
- Chemistry Documentation: Application/compendial release, batch records, $3\,months$ accelerated stability data, and long-term stability data.
- Dissolution Testing: Multi-point dissolution testing.
- Bioequivalence Testing: Full in vivo bioequivalence study (unless waiver is formally justified).
- Filing: Prior Approval Supplement (PAS) with accelerated stability data; Annual Report with long-term stability data.

2. Site Changes (Manufacturing Location Changes)

Level 1 Changes:
- Definition: Site change within a single facility using identical equipment, SOPs, environmental conditions, and personnel, with no changes to batch records except administrative details.
- Testing: None beyond application/compendial release.
- Filing: Annual Report.
Level 2 Changes:
- Definition: Site change within a contiguous campus or adjacent city blocks using identical equipment, SOPs, environmental conditions, and personnel, with no batch record changes except administrative details.
- Chemistry Documentation: Location of new site, updated batch records, long-term stability data for $1\,batch$ in Annual Report.
- Dissolution & Bioequivalence Testing: None beyond application/compendial requirements.
- Filing: Changes Being Effected (CBE) supplement; Annual Report with long-term stability data.
Level 3 Changes:
- Definition: Site change to a different campus or non-adjacent location, using same equipment, SOPs, environmental conditions, and controls, with no batch record changes except administrative details.
- Chemistry Documentation: Location of new site, updated batch records, stability data ( $1\,batch$ with $3\,months$ accelerated and $1\,batch$ long-term; up to $3\,batches$ for both if needed).
- Dissolution Testing: Multi-point dissolution profile to establish profile similarity between original and new sites.
- Bioequivalence Testing: None.
- Filing: Prior Approval Supplement (PAS); Annual Report with long-term stability data.

3. Changes in Batch Size (Scale-Up / Scale-Down)

General Parameter Scope: Scale-down below $100,000$ dosage units is not covered by these guidelines. All scale-up operations must be validated and inspected if required.
Level 1 Changes:
- Definition: Batch size change up to $10 \times$ (10 times) the pilot/biobatch size, utilizing identical equipment, SOPs, and controls.
- Chemistry Documentation: Application/compendial requirements, updated batch records in Annual Report, $1\,batch$ long-term stability.
- Dissolution & Bioequivalence: None beyond compendial requirements.
- Filing: Annual Report with long-term stability data.
Level 2 Changes:
- Definition: Batch size change greater than $10 \times$ (10 times) the pilot/biobatch size, utilizing identical equipment, SOPs, and controls.
- Chemistry Documentation: Application/compendial requirements, updated batch records, $1\,batch$ with $3\,months$ accelerated stability, $1\,batch$ long-term stability.
- Dissolution Testing: Case B dissolution profile testing.
- Bioequivalence Testing: None.
- Filing: Changes Being Effected (CBE) supplement; Annual Report with long-term stability data.

4. Manufacturing Changes: Equipment

Level 1 Changes:
- Definition: Transition from non-automated to automated/mechanical equipment, OR switching to alternative equipment with identical design and operating principles.
- Chemistry Documentation: Application/compendial release, updated batch records, $1\,batch$ long-term stability.
- Dissolution & Bioequivalence: None beyond standard compendial requirements.
- Filing: Annual Report with long-term stability data.
Level 2 Changes:
- Definition: Switching to manufacturing equipment featuring different design and operating principles.
- Chemistry Documentation: Application/compendial requirements, updated batch records, $1\,batch$ with $3\,months$ accelerated stability, $1\,batch$ long-term stability (up to $3\,batches$ for both if significant data is not available).
- Dissolution Testing: Case C dissolution profiling.
- Bioequivalence Testing: None.
- Filing: CBE supplement with technical justification; Annual Report with long-term stability data.

5. Manufacturing Changes: Process

Level 1 Changes:
- Definition: Process parameter adjustments remaining within established application/validation ranges (e.g., mixing times, operating speeds).
- Testing: None beyond application/compendial requirements.
- Filing: Annual Report.
Level 2 Changes:
- Definition: Process parameter changes operating outside approved application/validation ranges.
- Chemistry Documentation: Application/compendial release, updated batch records, $1\,batch$ long-term stability.
- Dissolution Testing: Case B dissolution profile testing.
- Bioequivalence Testing: None.
- Filing: Changes Being Effected (CBE) supplement; Annual Report with long-term stability data.
Level 3 Changes:
- Definition: Change in the fundamental type of manufacturing process (e.g., changing from wet granulation to direct compression).
- Chemistry Documentation: Application/compendial release, updated batch records, $1 \text{ to } 3\,batches$ with $3\,months$ accelerated stability and long-term stability data.
- Dissolution Testing: Case B dissolution profile testing.
- Bioequivalence Testing: Full in vivo bioequivalence study (can be waived if in vivo/in vitro correlation [IVIVC] is verified).
- Filing: Prior Approval Supplement (PAS) with justification; Annual Report with long-term stability data.

6. Specification Changes

Scope: Adjustments to approved analytical criteria, test procedures, and standards ensuring quality of drug products, raw materials, and components.
Major Change (PAS): Relaxing an acceptance criterion; deleting part of an approved specification.
Moderate Changes:
- CBE-30: Relaxing acceptance criteria for raw materials.
- CBE-0: Tightening a specification to ensure greater analytical certainty.
Minor Changes (AR): Narrowing acceptance criteria.

7. Container and Closure System Changes

Scope: Modifications to primary or secondary packaging systems responsible for protection and identification.
Major Change (PAS): Altering a primary packaging component; switching from single-unit dosage to multi-dose container.
Moderate Changes:
- CBE-30: Changing dimensions or shape of a sterile product container.
- CBE-0: Adding or omitting a desiccant.
Minor Changes (AR): Changing cap liner; adding a lid liner; increasing container wall thickness.

8. Labeling Changes

Scope: Modifications to NDA/ANDA labeling, layout, branding, or package inserts.
Major Change (PAS): Label modifications based on post-marketing performance data, such as adding new indications.
Moderate Changes:
- CBE-30: Adding or reinforcing dosage instructions to enhance safer administration.
- CBE-0: Updating prescribing information to match the Reference Listed Drug (RLD) label.
Minor Changes (AR): Altering label format or layout without changing substantive text/content.

9. Miscellaneous Changes

Major Change (PAS): Adding a comparability protocol or stability protocol.
Moderate Changes (CBE-30): Reducing the product expiry date to ensure product quality.
Minor Changes (AR): Extending the product expiry date based on full shelf-life stability data.

Detailed Categorical Examples Matrix

Excipient & Formulation Composition Changes

Level 1 (Minor):
- Minor increase in binder amount in a tablet formulation (e.g., increasing PVP from $2\%$ to $2.5\%$ ).
- Adjustment of flavoring agent concentration within approved ranges.
- Change in excipient grade (e.g., switching from microcrystalline cellulose grade 101 to grade 102).
- Substitution of a colorant within the same approved FDA colorant list.
- Reduction in surfactant concentration in an oral solution (e.g., reducing polysorbate from $1\%$ to $0.9\%$ ).
Level 2 (Moderate / Intermediate):
- Replacement of lactose with mannitol as a filler in tablets.
- Switching from corn starch to potato starch as a disintegrant.
- Changing lubricant type (e.g., switching from magnesium stearate to stearic acid).
- Substitution of one preservative for another (e.g., replacing methylparaben with benzyl alcohol).
- Modification in component ratios within a controlled-release formulation.
Level 3 (Major):
- Addition of a new antioxidant not previously included in formulation.
- Complete removal of a surfactant from an emulsion formulation.
- Inclusion of a new therapeutic agent in a combination drug product.
- Substitution of an inactive ingredient with a different functional class (e.g., replacing a disintegrant excipient with a binder excipient).
- Addition of a new flavor or fragrance not previously approved by regulatory authorities.

Manufacturing Site Changes

Level 1 (Minor):
- Moving tableting operations to another room within the same facility.
- Shifting packaging activities from one section of a plant to another section.
- Transferring analytical testing to another laboratory within the same building.
- Changing raw material storage locations within the same site.
- Reallocating finished product warehousing space within the same facility.
Level 2 (Moderate / Intermediate):
- Relocating the entire manufacturing process to another facility owned by the same company in the same region.
- Transferring packaging operations to a different plant within the same company.
- Moving analytical testing operations to a different site owned by the same corporation.
- Shifting secondary component production (e.g., capsule shells) to a different site within the same company.
- Changing storage warehouse to a new facility owned by the same company.
Level 3 (Major):
- Outsourcing drug production to a third-party contract manufacturer.
- Transferring packaging and labeling operations to an external partner.
- Relocating manufacturing operations to a different country under a different legal entity.
- Engaging a different corporate entity for the chemical synthesis of the Active Pharmaceutical Ingredient (API).
- Shifting primary manufacturing operations to a facility owned by a different organization.

Batch Size Changes

Level 1 (Minor):
- Increasing batch size by $8\%$ without changing equipment or process parameters.
- Reducing batch size by $5\%$ while keeping equipment and parameters identical.
- Producing $10\%$ more dosage units in the same production run.
- Slight batch size decrease due to process optimization (e.g., wastage reduction).
- Increasing batch size slightly to align with production efficiency targets.
Level 2 (Moderate / Intermediate):
- Scaling up production by $30\%$ with minor adjustments to process parameters.
- Decreasing batch size by $40\%$ while maintaining identical equipment.
- Increasing batch size by $25\%$ to meet higher market demand.
- Adjusting batch size to accommodate a new shift, resulting in a $35\%$ increase.
- Scaling down batch size by $20\%$ due to temporary raw material shortages.
Level 3 (Major):
- Scale-up beyond standard guideline validation boundaries necessitating fundamental re-validation or structural equipment redesign.

Equipment Changes

Level 1 (Minor):
- Replacing a tablet press with another unit of the same model from a different manufacturer.
- Substituting a homogenizer with a newer version of the exact same model.
- Upgrading to a newer version of a coating pan with similar design specifications.
- Switching to a different brand of blender possessing identical capacity and mixing efficiency.
- Changing an encapsulating machine to one of identical design and operating capacity.
Level 2 (Moderate / Intermediate):
- Changing from a fluid bed granulator to a high-shear granulator.
- Replacing a rotary tablet press with a hydraulic tablet press.
- Switching from a double-cone blender to a ribbon blender.
- Switching coating equipment types (e.g., from perforated to non-perforated pan).
- Changing from a conventional dryer to a vacuum dryer with similar drying capabilities.
Level 3 (Major):
- Switching from wet granulation to direct compression, requiring entirely different operational equipment.
- Replacing a conventional batch mixer with an automated continuous mixer.
- Changing from a batch to a continuous manufacturing process requiring complete equipment replacement.
- Transitioning from traditional mechanical milling to cryogenic milling equipment.
- Switching sterilization methods from steam sterilization to gamma irradiation equipment.

Process Changes

Level 1 (Minor):
- Minor increase in blending mixing time.
- Adjustment of drying temperature within validated parameter ranges.
- Slight modification in granulation time to achieve better uniformity.
- Increasing tablet press speed slightly to optimize production.
- Changing the order of excipient addition during the granulation step.
Level 2 (Moderate / Intermediate):
- Changing sequence of mixing active and inactive ingredients.
- Altering granulation method from wet granulation to dry granulation.
- Modifying drying process from oven drying to fluid bed drying.
- Switching sterilization method from filtration sterilization to heat sterilization.
- Implementing a new coating process to enhance tablet stability.
Level 3 (Major):
- Converting a batch manufacturing process to continuous manufacturing involving major process re-engineering.
- Introducing a new sterilization technique (e.g., irradiation instead of autoclaving).
- Changing from batch-wise granulation to continuous wet granulation.
- Switching drug release mechanism from immediate-release to sustained-release formulation.
- Adopting a new encapsulation process that fundamentally alters the drug bioavailability profile.

Specification Changes

Level 1 (Minor):
- Narrowing the range of tablet hardness in quality control release specifications.
- Tightening acceptable $pH$ ranges for liquid formulations.
- Reducing allowable moisture content specifications in lyophilized products.
- Narrowing specification limits for particle size distribution.
- Tightening assay acceptance criteria for the active ingredient.
Level 2 (Moderate / Intermediate):
- Broadening dissolution time range within approved regulatory limits.
- Increasing allowable variation limits for tablet weight.
- Widening acceptance criteria limits for minor degradation products.
- Changing specification acceptance limits for residual solvent content.
- Modifying acceptable impurity limits based on newly acquired stability data.
Level 3 (Major):
- Introducing a new specification for a degradation product not previously evaluated.
- Adding a new analytical test for particle size distribution in a suspension.
- Establishing specifications for a polymorphic form of the active ingredient.
- Implementing a new test for sterility for a previously non-sterile drug product.
- Changing dissolution profile specifications to reflect a modified release mechanism.

Label Changes

Level 1 (Minor):
- Updating corporate logo on product label packaging.
- Correcting typographical errors in instructions for use.
- Adding non-critical promotional taglines or non-regulatory statements.
- Executing minor layout or formatting changes to improve label readability.
- Revising packaging color scheme without modifying approved label text.
Level 2 (Moderate / Intermediate):
- Changing dosage administration instructions within approved parameter ranges.
- Adding new storage temperature/condition instructions based on stability data.
- Altering directions for use to include additional routes of administration.
- Revising label to include dosing information for a newly approved age demographic.
- Updating label details for a new use case within the same therapeutic category.
Level 3 (Major):
- Adding new warning statements or contraindications based on post-marketing surveillance.
- Incorporating a new mandatory Black Box Warning required by regulatory agencies.
- Changing the primary therapeutic indication of the drug product.
- Adding new pharmacokinetic drug-drug interaction warnings.
- Inclusion of new serious adverse event information previously unknown.

Packaging Material Changes

Level 1 (Minor):
- Replacing HDPE bottles with PET bottles having similar barrier protection properties.
- Switching from one brand of HDPE bottle to another brand with identical specifications.
- Changing cap material from one plastic type to another within the exact same category.
- Minor modification in blister foil thickness without changing protective function.
- Switching cardboard suppliers for secondary outer packaging.
- Changing label adhesive material without altering label durability or readability.
Level 2 (Moderate / Intermediate):
- Switching blister packaging material from PVC to PVDC-coated PVC.
- Utilizing a new child-resistant closure system composed of different materials.
- Changing primary packaging materials for sterile products (e.g., glass vials to plastic vials).
- Changing topical product containers from plastic tubes to aluminum tubes.
Level 3 (Major):
- Switching primary packaging container from bottles to blister packs.
- Changing primary injectable packaging from glass ampoules to pre-filled syringes.
- Replacing liquid packaging containers from bottles to unit-dose pouches.
- Switching nasal spray containers from multi-dose to single-dose packaging.
- Changing topical primary packaging from metal cans to laminated tubes.

Practice Questions and Self-Assessment

Section 1: Composition & Component Changes

1.1. Which of the following is an example of a Level 1 composition change?
- A) Addition of a new preservative
- B) Minor increase in the amount of a binder
- C) Replacement of lactose with mannitol
- D) Addition of a new antioxidant
- Answer: B
1.2. Which of the following would be considered a Level 2 change in composition?
- A) Increasing the concentration of a colorant within approved limits
- B) Replacement of lactose with mannitol as a filler
- C) Addition of a new flavor
- D) Complete removal of a surfactant
- Answer: B
1.3. Which of these changes represents a Level 3 change in composition?
- A) Substitution of one preservative for another
- B) Adjustment of a flavoring agent concentration
- C) Tightening the acceptance criteria for tablet hardness
- D) Addition of a new therapeutic agent in a combination product
- Answer: D
1.4. What is an example of a Level 2 composition change?
- A) Minor reduction in the amount of a surfactant
- B) Substitution of cornstarch with potato starch as a disintegrant
- C) Changing the grade of an excipient
- D) Addition of a new therapeutic agent
- Answer: B
1.5. Which of the following is a Level 1 composition change?
- A) Addition of a new preservative
- B) Reduction in the amount of a surfactant in an oral solution
- C) Inclusion of a new flavor
- D) Replacement of lactose with mannitol
- Answer: B

Section 2: Site Changes

2.1. Which example best represents a Level 1 site change?
- A) Moving tableting operations to another room within the same facility
- B) Transferring packaging operations to a different plant within the same company
- C) Outsourcing production to a third-party manufacturer
- D) Relocating manufacturing to a different country under a different legal entity
- Answer: A
2.2. Which of the following is a Level 2 site change?
- A) Moving analytical testing to another lab in the same building
- B) Transferring packaging operations to a different plant within the same company
- C) Moving primary manufacturing operations to a facility owned by a different organization
- D) Shifting production to another room within the same site
- Answer: B
2.3. Which of the following is considered a Level 3 site change?
- A) Shifting the storage location for raw materials within the same site
- B) Reallocating warehousing space for finished products within the same facility
- C) Outsourcing production to a third-party contract manufacturer
- D) Transferring analytical testing operations to a different site within the same corporation
- Answer: C
2.4. What is an example of a Level 2 site change?
- A) Moving tableting operations to another room within the same facility
- B) Relocating the entire manufacturing process to another facility owned by the same company
- C) Shifting packaging activities from one section of a plant to another
- D) Moving primary manufacturing operations to a facility owned by a different organization
- Answer: B
2.5. Which of the following changes is a Level 1 site change?
- A) Changing the storage location for raw materials within the same site
- B) Transferring packaging operations to a different plant within the same company
- C) Relocating manufacturing to a different country under a different legal entity
- D) Outsourcing production to a third-party manufacturer
- Answer: A

Section 3: Change in Batch Size

3.1. Which of the following is an example of a Level 1 change in batch size?
- A) Doubling the batch size to transition from pilot-scale to commercial-scale manufacturing
- B) Increasing the batch size by $8\%$ without changing the equipment or process parameters
- C) Scaling up production by $30\%$ with minor adjustments to process parameters
- D) Decreasing batch size by $60\%$ to produce a specialized small batch for clinical trials
- Answer: B
3.2. What is an example of a Level 2 change in batch size?
- A) Tripling the batch size for a high-demand product, necessitating significant process modifications
- B) Scaling up production by $30\%$ with minor adjustments to process parameters
- C) Minor reduction in the batch size due to optimization of the process
- D) Slight increase in batch size to align with production efficiency goals
- Answer: B
3.3. Which of these is an example of a Level 2 change in batch size?
- A) Minor increase in batch size by $5\%$ while keeping the same equipment and process
- B) Decreasing batch size by $40\%$ while using the same equipment
- C) Tripling the batch size for a high-demand product, necessitating significant process modifications
- D) Reducing batch size by $60\%$ to produce a specialized small batch for clinical trials
- Answer: B
3.4. Which of the following would be classified as a Level 1 batch size change?
- A) Slight decrease in batch size due to optimization of the process
- B) Doubling the batch size to transition from pilot-scale to commercial-scale manufacturing
- C) Scaling down batch size by $20\%$ due to a temporary reduction in raw material availability
- D) Tripling the batch size for a high-demand product, necessitating significant process modifications
- Answer: A

Section 4: Change in Equipment

4.1. Which of the following is an example of a Level 1 change in equipment?
- A) Replacing a tablet press with another of the same model from a different manufacturer
- B) Changing from a fluid bed granulator to a high-shear granulator
- C) Switching from wet granulation to direct compression
- D) Replacing a conventional mixer with an automated continuous mixer
- Answer: A
4.2. What is an example of a Level 2 equipment change?
- A) Changing from a fluid bed granulator to a high-shear granulator
- B) Switching from wet granulation to direct compression, requiring entirely different equipment
- C) Moving from traditional milling equipment to cryogenic milling
- D) Replacing a conventional mixer with an automated continuous mixer
- Answer: A
4.3. Which of these is a Level 3 change in equipment?
- A) Upgrading to a newer version of a coating pan with similar specifications
- B) Replacing a rotary tablet press with a hydraulic tablet press
- C) Switching from wet granulation to direct compression, requiring entirely different equipment
- D) Substituting a homogenizer with a newer version of the same model
- Answer: C
4.4. Which of the following is an example of a Level 2 change in equipment?
- A) Replacing a rotary tablet press with a hydraulic tablet press
- B) Upgrading to a newer version of a coating pan with similar specifications
- C) Switching from steam sterilization to a gamma irradiation process, requiring different equipment
- D) Switching from a double-cone blender to a ribbon blender
- Answer: A
4.5. Which example best represents a Level 1 change in equipment?
- A) Upgrading to a newer version of a coating pan with similar specifications
- B) Moving from traditional milling equipment to cryogenic milling
- C) Changing from wet granulation to direct compression
- D) Switching from steam sterilization to a gamma irradiation process, requiring different equipment
- Answer: A

Section 5: Change in Process

5.1. Which of the following is an example of a Level 1 process change?
- A) Minor increase in mixing time during blending
- B) Converting a batch process to a continuous process
- C) Implementing a new coating process to improve tablet stability
- D) Switching the drug release mechanism from immediate-release to sustained-release formulation
- Answer: A
5.2. What is an example of a Level 2 process change?
- A) Changing the order of addition of excipients in the granulation step
- B) Modifying the drying process from oven drying to fluid bed drying
- C) Introducing a new sterilization technique such as irradiation instead of autoclaving
- D) Converting a batch process to a continuous process
- Answer: B
5.3. Which of the following is an example of a Level 3 process change?
- A) Slight modification in granulation time for better uniformity
- B) Adjustment of the drying temperature within validated ranges
- C) Changing from batch-wise granulation to continuous wet granulation
- D) Minor increase in mixing time during blending
- Answer: C
5.4. Which of the following is a Level 2 process change?
- A) Changing the sequence of mixing active and inactive ingredients
- B) Altering the granulation method from wet to dry granulation
- C) Implementing a new coating process to improve tablet stability
- D) Converting a batch process to a continuous process
- Answer: B
5.5. Which of the following is an example of a Level 1 process change?
- A) Slight modification in the mixing speed during blending
- B) Changing from wet to dry granulation
- C) Converting a batch process to a continuous process
- D) Switching from a heat sterilization process to a filtration sterilization process
- Answer: A

Section 6: Specification Changes

6.1. Which of the following represents a Level 1 change in specification?
- A) Tightening the acceptance criteria for appearance attributes
- B) Reducing the allowable range for drug potency
- C) Expanding the acceptance criteria for dissolution to include a wider range
- D) Adding a new specification for an impurity
- Answer: A
6.2. What is an example of a Level 2 change in specification?
- A) Widening the acceptance criteria for friability of tablets
- B) Reducing the allowable range for drug potency
- C) Changing the test method for determining water content
- D) Implementing a new test for sterility
- Answer: A
6.3. Which of the following would be considered a Level 3 specification change?
- A) Adding a new specification for an impurity
- B) Tightening the acceptance criteria for appearance attributes
- C) Reducing the allowable range for drug potency
- D) Expanding the acceptance criteria for dissolution to include a wider range
- Answer: A
6.4. What is an example of a Level 2 specification change?
- A) Adding a new specification for an impurity
- B) Expanding the acceptance criteria for dissolution to include a wider range
- C) Implementing a new test for sterility
- D) Tightening the acceptance criteria for appearance attributes
- Answer: B
6.5. Which of the following represents a Level 1 change in specification?
- A) Tightening the acceptance criteria for appearance attributes
- B) Adding a new specification for an impurity
- C) Expanding the acceptance criteria for dissolution to include a wider range
- D) Implementing a new test for sterility
- Answer: A

Section 7: Label Changes

7.1. Which of the following is an example of a Level 1 label change?
- A) Correcting a typographical error in the instructions for use
- B) Adding a new black box warning mandated by regulatory authorities
- C) Revising the label to include information on a newly approved age group
- D) Incorporating a new contraindication based on post-marketing surveillance
- Answer: A
7.2. Which of the following is a Level 2 label change?
- A) Updating the company's logo on the product label
- B) Adding new storage instructions based on updated stability data
- C) Adding a new pharmacokinetic interaction with other drugs
- D) Incorporating a new black box warning mandated by regulatory authorities
- Answer: B
7.3. Which of the following would be considered a Level 3 label change?
- A) Revising the packaging color scheme without altering the label content
- B) Incorporating a new black box warning mandated by regulatory authorities
- C) Correcting a typographical error in the instructions for use
- D) Adding new non-critical information (e.g., a promotional tagline)
- Answer: B
7.4. Which of the following is an example of a Level 2 label change?
- A) Altering the usage directions to include additional administration routes
- B) Correcting a typographical error in the instructions for use
- C) Updating the company's logo on the product label
- D) Incorporating a new contraindication based on post-marketing surveillance
- Answer: A
7.5. Which of the following is an example of a Level 1 label change?
- A) Updating the company's logo on the product label
- B) Adding a new pharmacokinetic interaction with other drugs
- C) Changing the dosage instructions within the approved range
- D) Revising the label to include information on a newly approved age group
- Answer: A

Section 8: Packaging Material Changes

8.1. Which of the following represents a Level 1 change in packaging material?
- A) Switching from one brand of HDPE bottle to another with identical properties
- B) Replacing HDPE bottles with PET bottles of similar barrier properties
- C) Changing from a plastic tube to an aluminum tube for creams or ointments
- D) Switching from a bottle to a blister pack as the primary packaging
- Answer: A
8.2. What is an example of a Level 2 packaging material change?
- A) Replacing HDPE bottles with PET bottles of similar barrier properties
- B) Changing from a bottle to a blister pack as the primary packaging
- C) Changing the material for the primary packaging of sterile products
- D) Switching from a bottle to unit-dose pouches for a liquid product
- Answer: C
8.3. Which of the following is considered a Level 3 packaging material change?
- A) Changing the cap material from one type of plastic to another within the same category
- B) Switching from a bottle to a blister pack as the primary packaging
- C) Minor modification in the thickness of the blister foil without altering its protective function
- D) Switching the source of the cardboard for secondary packaging
- Answer: B
8.4. What is an example of a Level 2 packaging material change?
- A) Changing from a plastic tube to an aluminum tube for creams or ointments
- B) Switching from a bottle to unit-dose pouches for a liquid product
- C) Changing the packaging material from metal cans to laminated tubes for topical products
- D) Switching from multi-dose to single-dose packaging for a nasal spray
- Answer: A
8.5. Which of the following is a Level 1 packaging material change?
- A) Minor modification in the thickness of the blister foil without altering its protective function
- B) Switching from a bottle to a blister pack as the primary packaging
- C) Replacing HDPE bottles with PET bottles of similar barrier properties
- D) Changing the material for the primary packaging of sterile products
- Answer: A